Executives from Aclaris Therapeutics (NASDAQ:ACRS) outlined the company’s clinical-stage pipeline and upcoming catalysts ...

Maternal respiratory syncytial virus vaccination appeared to be safe and effective for mothers with HIV and their infants, according to data presented at the Conference on Retroviruses and ...

Corbus Pharmaceuticals (NASDAQ:CRBP) outlined a “catalyst-rich” 2026 at Oppenheimer’s 36th Annual Healthcare Conference, with ...

These phase IIb results reinforce lotivibart’s ultra long-acting potential, with the trial progressing to evaluate a twice-yearly intravenous dosing interval ...

ViiV Healthcare has reported several successful HIV trials at CROI 2026, including its investigational candidates lotivibart, ...

VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an ...

Feb 26 (Reuters) - Drugmaker Viatris forecast annual profit below analysts' expectations on Thursday, after a fire at one of its major plants in India disrupted operations. A fire occurred at the ...

Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

Industry leaders met in San Diego to debate whether U.S. biotechs are losing ground to China. Meanwhile, across the Pacific, ...

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with ...

Dr. Vinay Prasad, vaccine chief at the the U.S. Food and Drug Administration (FDA), said in an internal memo in November that ...